Full text is available at the source.
SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose‐lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review
SGLT2 inhibitors and GLP1 agonists without metformin compared to other diabetes drugs for preventing heart problems in type 2 diabetes
AI simplified
Abstract
In a meta-analysis of five randomized clinical trials involving 50,725 type 2 diabetes patients, SGLT2 inhibitors reduced the risk of major adverse cardiovascular events (MACE) by 32% compared to placebo.
- GLP1-RAs reduced the risk of MACE by 20% in patients without metformin at baseline.
- The analysis included 10,013 type 2 diabetes patients who had not received metformin.
- Three studies focused on GLP1-RAs while two focused on SGLT2 inhibitors.
- Both treatments may provide cardiovascular benefits for type 2 diabetes patients at increased risk of events.
AI simplified